A NEW spin-off company from the University of Southampton aims to revolutionise the diagnosis and treatment of hepatitis C and save the NHS millions of pounds.
HepCgen has been founded by liver disease specialist Dr William Rosenberg, who has worked and researched in this field for 15 years.
Around 170 million people worldwide have hepatitis C and 30,000 new cases were diagnosed in 2001. Five times more prevalent than HIV, it is transmitted through blood, frequently as a result of shared needles.
If fibrosis, or scarring of the liver, is not detected early, the disease can result in organ failure and death through cirrhosis. Effective treatment is now available but this has side effects and is costly.
Dr Rosenberg said: "It has been called the silent epidemic because people are not aware of the problem and because most infections go undetected. Even patients are reluctant to talk about it although it is a very common condition.
"New tests and treatments are desperately needed and we are confident our research will make a major contribution to beating hepatitis C.
"HepCgen's tests help tailor treatments to suit individual patients. Some patients have a hepatitis C viral infection that can be treated for just six months while others need treatment for a year to gain the same benefit. HepCgen's tests can also help identify patients who are unlikely to respond to treatment early on. Dr Rosenberg believes the NHS could save half a billion pounds a year if doctors routinely use his new test.
"Making the correct diagnosis early on avoids the possibility of the patient being put through months of needless treatment, including unpleasant side effects, and the waste of expensive drugs,'' he said.
In addition to diagnostic tests HepCgen is aiming to develop new treatments for hepatitis C. HepCgen has received £350,000 in seedcorn funding primarily from the Southampton Asset Management Fund. Dr Rosenberg's research team has already raised more than £3m in funding over the past four years. He has worked in immunology and liver disease at the University of Southampton since 1997, after extensive study and research in Oxford.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article